Modality
Nanobody
MOA
HPK1i
Target
CD19
Pathway
Innate Imm
Parkinson'sET
Development Pipeline
Preclinical
Sep 2024
PreclinicalCurrent
NCT08462786
1,605 pts·Parkinson's
2024-09→TBD·Completed
1,605 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08462786 | Preclinical | Parkinson's | Completed | 1605 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |